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Introduction
Survival of children after a relapse of acute myeloid
leukemia (AML) is generally poor1,2 but has improved for
seve ral groups over the last 20 years along with better treat-
ment approaches.3-7 The most recently published study
reported a probability of survival after relapse of only 38% at
4 years.8 In general, patients who relapse are currently treated
with very intensive reinduction chemotherapy followed by
hematopoietic stem cell transplantation from either a related
or unrelated donor.3,6
Until now the time to relapse or the duration of first com-
plete remission has been considered the most important prog-
nostic factor for outcome after relapse in pediatric AML.6,9,10
The 3- to 5-year survival rates are reported to be in the range
of only 10 to 28% in patients who have an early relapse
(relapse occurring within 12 – 18 months from diagnosis)
compared to 40-48% in those whose relapse occurs later.7,8,10
Other factors described to be prognostic in the relapse setting
are French-American-British subtypes, cytogenetics and
intensity of first-line treatment, particularly with or without
allogeneic hematopoietic stem cell transplantation.5-7
A good early treatment response in newly diagnosed AML,
whether assessed morphologically, molecularly or by
immunophenotyping, is accepted as a favorable prognostic
indicator, but the significance of early response in relapsed
AML in children has not previously been studied. Our aim
was to compare the prognostic significance of early treatment
response at day 15 and day 28 in order to identify those
patients who have only minimal chances of cure with current
(standard) relapse therapy. This was studied within the inter-
national trial, Relapsed AML 2001/01.8
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The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute
myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treat-
ment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28
after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 sta-
tus was classified as good (≤20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast
percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P<0.001). Survival probability
decreased in a stepwise fashion along with rising blast counts at day 28. Patients with bone marrow blast counts
at this time-point of  ≤5%, 6-10%, 11-20% and >20% had 4-year probabilities of survival of 52%±3% versus
36%±10% versus 21%±9% versus 14%±4%, respectively, P<0.0001; this trend was not seen for day 15 results.
Multivariate analysis showed that early treatment response at day 28 had the strongest prognostic significance,
superseding even time to relapse (< or ≥12 months). In conclusion, an early response to treatment, measured on
day 28, is a strong and independent prognostic factor potentially useful for treatment stratification in pediatric
relapsed acute myeloid leukemia. This study was registered with ISRCTN code: 94206677.
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ABSTRACT
Methods
Between November 2001 and April 2009, 568 patients under 21
years old of age were enrolled into the prospective international
study, Relapsed AML 2001/01: these patients came from 13 study
groups and 515 had a first relapse while 53 had primary refractory
AML.8 Patients with acute promyelocytic leukemia and myeloid
leukemia in Down syndrome were not included. This analysis
was based on 546 patients, because 22 patients with isolated
extramedullary relapse were excluded.
Early treatment response was evaluated microscopically by
bone marrow (BM) blast percentage on day 15 and day 28 of first
reinduction (for details see the Online Supplement). The core group
for this analysis consisted of 338 patients with data from BM
examinations on both day 15 and day 28. Day 15 BM findings did
not influence subsequent therapy, while patients with more than
20% blasts on day 28 were off-protocol and eligible for more
experimental or even palliative therapy.
The human investigations were performed after approval by all
local ethical committees and by the departments of Health and
Human Services and in accordance with the Declaration of
Helsinki (ISRCTN code: 94206677). 
Treatment
Reinduction therapy with fludarabine, cytarabine, and granu-
locyte colony-stimulating factor (FLAG) was randomized against
FLAG plus liposomal daunorubicin (L-DNR/FLAG) in first rein-
duction. L-DNR (DaunoXome®, DNX) was chosen because of its
potentially low cardiotoxicity.8 Second reinduction for all
patients was scheduled with FLAG. Patients with ≤20% blasts
on day 28 were given consolidation with cytarabine and etopo-
side or thioguanine and cytarabine to bridge the time until
hematopoietic stem cell transplantation. Patients with >20%
blasts on day 28 were “off study” and could receive new thera-
peutic options.
Definitions
Second complete remission was defined as ≤5% leukemic blasts
in the BM with regeneration of the peripheral blood counts
(platelets >50x109/L, neutrophils >1.0x109/L) and no leukemic
blasts. Primary refractory disease was defined as the failure to
achieve complete remission in newly diagnosed AML. Relapse
was considered to have occurred in the presence of recurrence of
≥10% unequivocal leukemic cells in BM, and/or leukemic infiltra-
tions at any site after the first complete remission. Early relapse
was defined as a relapse occurring within 1 year, whereas a late
relapse was defined as a relapse occurring 1 year or more after the
initial diagnosis. Poor early treatment response was defined by a
BM blast count of >20% after induction (on day 15 or day 28). The
morphological favorable subgroups were French-American-British
subtype M1/2 with Auer rods and M4eo,11 while favorable cyto-
genetics were t(8;21) or inv(16).
Statistics 
The primary endpoint of the study was the day 28 BM status.
Secondary endpoints were day 15 BM status, second complete
remission and long-term survival. Overall survival was defined as
the time to death or last follow-up. The Kaplan-Meier method
was used to estimate survival rates; differences were compared
with the two-sided log-rank test. Differences in proportions were
assessed by the c2 test. The Cox proportional hazards model was
used for univariate and multivariate analyses. P values ≤0.05 were
considered statistically significant, and if >0.05 but ≤0.10 of bor-
derline statistical significance. Results are presented as estimated
probability of 4-year overall survival with standard error (± SE). All
living patients were censored at time of their last follow-up, but no
later than January 1, 2011.
Results 
Patients’ characteristics
Of the 496 patients for whom day 28 data were avail-
able, 338 patients also had data for day 15. Comparing this
core-group of 338 patients (data available from both day
15 and day 28) with all the other patients (n=208), the lat-
ter cohort contained fewer patients with favorable cytoge-
netics (P=0.01) or favorable morphology (P=0.01), and
fewer patients with a late relapse (P<0.001) or younger age
(P<0.001). White blood cell counts were not different
between these cohorts (Online Supplementary Table S1).
The survival rates were inferior in the 208 patients with-
out data from both time points than in the core group (4-
year probability of overall survival 30%±3% versus 41%
±3%, Plogrank=0.0003). This difference can be partially
explained by the fact that patients who died early could
not be evaluated on day 15 and day 28. 
Table 1 shows the characteristics of the core cohort
(n=338) with BM data on day 15 and day 28. Subgroups of
patients with favorable morphology and favorable cytoge-
netics more often had ≤20% blasts on day 15 (P=0.001 and
P=0.0001, respectively) and on day 28 (P=0.0001 and
P≤0.00001, respectively). Only 2/71 (3%) patients with
favorable cytogenetics had ≥20% blasts on day 28 com-
pared to 69/240 (29%) patients with other cytogenetic
findings. 
Whereas the treatment response measured on day 15
did not clearly differ between patients according to time to
relapse [early relapse ≥20% blasts, n=39/146 (27%) versus
late relapse n= 36/170 (21%) P=0.28], significantly more
patients with an early relapse (n=47/146, 32%) had a poor
treatment response on day 28 compared to those with late
relapse (n=24/170, 14%, P=0.00017).
Correlation between the bone marrow blast counts 
on days 15 and 28
Table 2 shows the correlation between the BM blast
counts on day 15 and day 28 in patients with data at both
time points. Remarkably few patients were allocated to
the subgroups with 6-10% and 11-20% blasts at both time
points. The blast percentages on day 15 and day 28 corre-
lated significantly, but not very strongly (Spearman corre-
lation coefficient=0.49, P<0.001). The majority of patients
with ≤20% blasts on day 15 (n=261) also had ≤20% blasts
on day 28 (231/261 = 89%, Table 2). However, 30 out of
77 (39%) patients with >20% blasts on day 15 had ≤20%
blasts on day 28. These 30 patients had a better outcome
than the remaining 47 patients (see below). Only 22 of the
77 patients (29%) with >20% blasts on day 28 had <5%
blasts on day 15. 
Outcome in patients according to response 
on day 15 and/or day 28
Seventy-seven percent of the 338 patients in the core
group showed a favorable response to reinduction (≤20%
blasts) both on day 15 and day 28. Overall, the 4-year sur-
vival in these core-group patients was 41±3%. There were
clear differences in survival rates between good and poor
responders at both time points (day 15: 47±3% versus 21±
5%, day 28: 48±3% versus 14±4%), showing a trend
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towards an even worse outcome in poor responders at day
28. Interestingly, while the survival rates were similar in
the subgroups with BM blast counts of 0-5%, 6-10% and
11-20% on day 15 (Figure 1), there was a significant, step-
wise trend to worsening survival with the categories of
increasing blast counts at day 28 (Figure 2) indicating that
the day 28 count is a more fine-tuned and reliable predic-
tor of survival (Table 3). When combining the BM data
from day 15 and day 28 (Figure 3), the combination “day
15 >20% blasts” but “day 28 <20% blasts” indicated an
intermediate survival probability after relapse, while
patients with ≤20% blasts on both day 15 and day 28 had
a higher survival rate, and patients with >20% blasts on
day 28 faced a very poor outcome regardless of the day 15
BM result.
Results according to achievement of second remission
One-hundred and five patients of the core group did not
achieve a second complete remission (4-year survival
13±3%) whereas 233 patients did (4-year survival 53±
3%, P(logrank) ≤0.0001). Patients with a poor early treatment
response on day 15 had a second complete remission rate
of 35%, while the rate was extremely low (10%) in those
with a poor response based on day 28 BM data. Second
complete remission rates mirrored survival rates in that
they fell proportionately with an increasing blast count on
day 28 rather than with the day 15 blast count (Table 3). 
Early treatment response in relation to the time 
to relapse 
Early treatment response appeared to have stronger
prognostic significance than time to relapse, since patients
with either an early or a late relapse and a day 28 BM blast
count of ≤20% had only a slightly different, relatively
favorable survival rate (4-year overall survival 41± 5% and
55±4%, respectively, P=0.05). Likewise, the survival of
patients with day 28 BM blast counts >20% was poor in
both patients with early and late relapses with 4-year
overall survival probabilities of 8±4% and 25±9%, respec-
tively (P=0.02) (Figure 4). However, it should be men-
tioned that a larger proportion of those with a late relapse
had a good response compared to those with an early
relapse (86% versus 68%, P<0.001). 
Multivariate analysis
In a model combining time to relapse (early versus late)
and BM status on day 15 and day 28 (poor versus good),
early treatment response, as determined on day 28, was the
strongest independent prognostic factor. In a Cox regression
analysis of survival adding cytogenetics, favorable cytoge-
netics was a strong prognostic factor (risk ratio 0.4, 95%
confidence interval 0.2-0.6; P<0.001), BM day 15 blast count
lost statistical significance (risk ratio 1.2, P=0.43), and a BM
day 28 blast count of >20 % (risk ratio 2.5, 95% confidence
interval 1.6-4.0; P<0.001) and early relapse (risk ratio 1.6,
U. Creutzig et al.
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Table 1. Characteristics of the cohorts of patients with ≤ or > 20% BM blasts on day 15 and day 28.
BM day 15 BM day 15 P value BM day 28 BM day 28 P value
≤ 20% > 20% ≤20% vs. >20% ≤ 20% > 20% ≤20%
vs. >20%
% % % %
N. of patients 261 77 77 23 261 77 77 23
Age at relapse 10.4 9.0 0.83 10.6 8.0 0.010
(years) median
Leukocytes at relapse* 3,700 3,900 0.15 3,600 3,900 0.30
(x109/L) median
(Q1-Q3) 2,100-7,700 2,600-12,600 2,100-7,900 2,300-10,000
Time to relapse 1.0 1.0 0.48 1.1 0.8 <0.001
(years) median
(Q1-Q3) 0.7-1.5 0.7-1.5 0.8-1.6 0.6-1.1
N. % N. % N. % N. %
Gender: male 148 57 43 56 0.89 146 56 45 58 0.70
FAB types*
M1/M2 Auer,  M4eo 92 38 13 18 0.001 95 39 10 14 0.0001
Other 150 62 61 82 151 61 60 86
Cytogenetic data* .
t(8;21), inv(16) 66 28 4 6 0.0001 68 29 2 3 <0.00001
Other 171 72 66 94 168 71 69 97
Site of relapse
BM isolated 213 85 72 94 0.04 219 86 66 88 0.69
BM combined 39 16 5 7 35 14 9 12
Early/late relapse
Early relapse 107 41 39 51 0.14 99 38 47 61 0.0006
Late relapse 134 51 36 47 146 56 24 31
Non-responder 20 8 2 3 16 6 6 8
Medians are given for continuous variables and absolute numbers for categorical values. FAB-type: French American British type, BM: bone marrow. Bold indicates significant P val-
ues. *Data were not available for all 338 patients: Leukocytes at relapse, n = 325; FAB at relapse n = 316; cytogenetics at relapse n = 307. 
95% confidence interval 1.2-2.3; P=0.005) each independ-
ently predicted poor outcome after relapse.
The prognostic value of blast count was independent of
the treatment effect. There was no significant interaction
between treatment effect (FLAG only versus L-
DNR/FLAG) and BM blast count on day 15 (P=0.3) or day
28 (P=0.4).
Comparison of day 28 data based on morphology 
and immunophenotyping 
In a limited subset of 20 patients including several
whose samples gave an uncertain morphological result at
day 28 we piloted a parallel assessment also by
immunophenotyping (for technical aspects, including the
antibody panel, see Langebrake et al.12).
In eight patients blasts had been suspected on the basis
of morphological studies; six of these cases were con-
firmed by immunophenotyping and two were found not
to be evaluable by immunophenotyping because of poor
material. Of 12 patients with no blasts by morphology,
seven were also negative by immunophenotyping, four
patients had 1-2% blasts and one patient had 20% blasts
by immunophenotyping. 
Discussion
Prognostic factors at diagnosis and relapse are most use-
ful if they influence treatment decisions. While no sub-
group has a sufficiently favorable outcome to justify treat-
ment reduction, intensive AML reinduction therapy cur-
rently leaves little room for treatment intensification.9
However, this may change upon the introduction of novel
drugs and treatment modalities. Moreover, the identifica-
tion of a subgroup with minimal chances of cure may
result in palliative or more experimental therapy.
Response to induction chemotherapy is a well-known
prognostic factor in de novo AML.11,13 However, the prog-
Early treatment response in pediatric relapsed AML 
haematologica | 2014; 99(9) 1475
Table 2. Correlation between the BM blast counts on day 15 and day 28.
Frequency
Percent
Row % BM day 28 BM day 28 BM day 28 BM day 28 Total
Column % 0-5 6-10 11-20 > 20
BM day 15 0-5% 173 11 7 22 213
51.2 3.3 2.1 6.5 63.0
81.2 5.2 3.3 10.3
78.6 50.0 36.8 28.6
BM day 15 6-10% 13 2 2 2 19
3.9 0.6 0.6 0.6 5.6
68.4 10.5 10.5 10.5
5.9 9.1 10.5 2.6
BM day 15 11-20% 18 5 0 6 29
5.3 1.5 0.00 1.8 8.6
62.1 17.2 0.00 20.7
8.2 22.7 0.00 7.8
BM day 15 >20% 16 4 10 47 77
4.7 1.2 3.0 13.9 22.8
20.8 5.2 13.0 61.0
7.3 18.2 52.6 61.0
Total 220 22 19 77 338
65.1 6.5 5.6 22.8 100.0
BM: bone marrow.
Table 3. Summary of achievement of second complete remission and 4-year
survival results according to day 15 and day 28 BM blasts counts.
BM blasts BM day 15 pOS (SE) BM day 28 pOS (SE)
% N. CR2 N (%) in % N. CR2 N (%) in %
0-5 213 174 (82) 46 (4) 223 203 (92) 52 (4)
6-10 19 12 (63) 52 (12) 23 10 (46) 35 (10)
11-20 29 20 (69) 47 (9) 19 12 (63) 21 (9)
>20 77 27 (35) 21 (5) 77 8 (10) 14 (4)
Total 338 233 (69) 41(3) 338 233 (69) 41(3)
CR2: second complete remission, BM: bone marrow; pOS: probability of overall survival; SE: stan-
dard error. Bold indicates the better discrimination based on BM day 28 status compared to BM
day 15 status.
Figure 1. Probability of 4-year survival after relapse according to
blast count on day 15. SE = standard error, 0-5% vs. >20%, P(logrank)
<0.0001; 6-10% vs. >20% P=0.011; 11-20% vs. >20% P=0.0011; all
other comparisons P>0.68.
Figure 2. Probability of 4-year survival after relapse according to blast
count on day 28. SE = standard error. 0-5% vs. 11-20%, P(logrank)
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nostic value of early treatment response in the setting of
pediatric relapsed AML has not previously been reported.
According to our results, the day 28 BM status is a strong
and independent prognostic factor, allowing an even bet-
ter discrimination into two risk groups than the time to
relapse, which until now has generally been considered to
be the most important risk factor.6,7,10 In this study, patients
with an early relapse but a good early treatment response
on day 28, which was observed in 68% of them, had a
long-term outcome which was only slightly inferior
(P=0.05) to that of patients with a late relapse and a good
early treatment response (Figure 4).
A blast count >20% at day 15 and day 28 is much com-
moner after relapse (occurring in 23% patients) than in de
novo AML (as compared with e.g. day 15 data from the
AML-BFM 2004 study: occurring in 37 of 499 patients,
7%; P<0.001), indicating increased resistance to
chemotherapy at relapse as compared to de novo AML.
Relapse per se is the strongest risk factor for survival and
there is no definable group with relapsed AML which has
an outcome sufficiently favorable to consider treatment
reduction. Indeed, patients with late relapses with a good
early treatment response only had a probability of overall
survival at 4 years of 55%. Our main aim was, therefore,
to identify a group of patients for which a poor survival
can be predicted early and reliably. This group of patients
with an estimated survival rate below 10-20% could be a
target for experimental therapy, e.g. treatment in phase I
or II studies for new agents or new hematopoietic stem
cell transplantation approaches, or even palliation only.
Day 28 blast count was already the primary endpoint
comparing FLAG or L-DNR/FLAG in the Relapsed AML
2001/01 study.8 The percentage of patients with >20%
blasts on day 28 was 10% lower in patients treated with L-
DNR/FLAG than in those treated with FLAG only; in corol-
lary, the rate of second complete remissions was higher
with L-DNR/FLAG, which thus improved the early
response rate significantly. This did not translate into better
survival rates in the L-DNR/FLAG group, which may be
related to cross-over effects with more treatment intensifi-
cation, especially in poor responders. However, this study
now shows that the prognostic value of the day 28 blast
count is not influenced by the treatment effect of L-DNR.
The percentage of patients with BM blast counts of
≤20% on days 15 and 28 was similar at 77%. Likewise,
the gaps between the 4-year survival rates of patients with
≤20% and >20% blasts on day 15 and day 28 were almost
similar. However, in contrast to the BM day 15 data,
which did not discriminate between different survival
rates in subgroups by blast count (0-5%, 6-10%, 11-20%),
there was a clear and significant trend to worse survival
with increasing BM blast counts on day 28. Thirty-nine
percent of patients with BM containing >20% blasts on
day 15 had ≤20% blasts in the BM on day 28, and this con-
version from poor to good early treatment response was
associated with a better outcome (Figure 3). This may be
explained by the fact that the usually aplastic day 15 BM
may still contain residual but non-proliferating leukemic
blasts which are bound to subsequent disappearance upon
delayed drug-action or to subsequent superimposition by
normal regeneration. Conversely, on day 28 normal
hematopoiesis is recovering and truly resistant leukemic
blasts could regrow together with normal progenitors. In
this situation and especially in patients with ≤20% blasts
on day 15, but with >20% blasts on day 28 (n=30, 14% of
patients) concurrent regeneration of both leukemic blasts
and normal progenitors may hamper correct assessment
by conventional morphological methods. Obviously, addi-
tional techniques, such as immunophenotyping and/or
genetic investigations could then be of relevant discrimi-
native value.14-16
Achievement of remission after relapse (second remis-
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Figure 3. Probability of 4-year survival after relapse combining blast
count data on day 15 and day 28. SE = standard error. BM day 15
≤20% and day 28 ≤20% vs. BM day 15 ≤20% and day 28 >20%,
P(logrank)<0.0001; BM day 15 ≤20% and day 28 ≤20% vs. BM day 15
>20% and day 28 ≤20% P=0.0070; BM day 15 ≤20% and day 28
≤20% vs. BM day 15 >20% and day 28 >20%, P<0.0001; BM day 15
≤20% and day 28 >20% vs. BM day 15 >20% and day 28 ≤20%,
P=0.0089; BM day 15 ≤20% and day 28 >20% vs. BM day 15 >20%
and day 28 >20%, P=0.76; BM day 15 >20% and day 28 ≤20% vs.
BM day 15 >20% and day 28 >20%, P=0.013.
Figure 4. Probability of 4-year survival after relapse according to time
of relapse and blast count on day 28. SE = standard error. Late
relapse and BM day 28 ≤20% vs. late relapse and BM day 28>20%,
P(logrank)=0.0004; late relapse and BM day 28 ≤20% vs. early relapse
and BM day 28 ≤20%, P=0.05; late relapse and BM day 28 ≤20% vs.
early relapse and BM day 28 >20%, P<0.0001; late relapse and BM
day 28 >20% vs. early relapse and BM day 28 ≤20%, P=0.028; late
relapse and BM 28 >20% vs. early relapse and BM day 28 >20%,
P=0.022; early relapse and BM 28 ≤20% vs. early relapse and BM
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sion) is essential for long-term survival. However, the time
point of an eventual second complete remission (according
to the classical definition of both BM and peripheral blood
parameters)17 may vary considerably because post-induc-
tion treatment of AML is often continued before all regen-
eration parameters needed to fulfill the criteria for com-
plete remission are reached.18 Therefore, from a clinical
point of view assessment of classical complete remission
will not allow timely treatment modifications. 
By multivariate analysis, favorable cytogenetics (present
in 23% of relapsed patients) was a strong favorable prog-
nostic factor: only two of 71 patients with favorable cyto-
genetics had >20% blasts on day 28, and 64 patients had
a blast count ≤5%. For the majority of patients, early treat-
ment response on day 28 was the strongest prognostic fac-
tor, which, at least partly, also superseded the time to
relapse. 
In brief, an early response, as assessed microscopically,
is an overriding prognostic factor in pediatric relapsed
AML – even in an internationally collaborative trial involv-
ing many sites. It is robust enough to discriminate
between subgroups with significantly different probabili-
ties of second complete remission and of overall survival.
This is of great relevance for the design of upcoming trials
because it allows for early treatment modifications in
selected cohorts of patients. Moreover, microscopic evalu-
ation is usually available in centers dedicated to care of
children with leukemia even in case of limited economic
or technical resources. 
Nevertheless, we are aware that morphological assess-
ment has limitations. First of all, investigator experience is
essential and even then, it remains a subjective method. A
well-known problem is the discrimination between nor-
mal blasts occurring with hyper-regeneration of progeni-
tors and leukemic blasts after aplasia. Also, low numbers
of leukemic blasts can be overlooked. In such situations,
other diagnostic methods, such as immunophenotyping,
can render additional information or proof of cellular
benignity.14-16 In a small and selected group of patients in
our study, there was a good concordance between blast
counts evaluated by morphology and immunophenotyp-
ing, but immunophenotyping was superior in evidencing
leukemic cells when the counts were <5% as well as even
in one case with 20% blasts which were misinterpreted
by morphology as being normal. False-positivity of mor-
phological findings was not an issue in this cohort.
Notably, immunophenotyping results were experimental
and not used for clinical decisions. 
In summary, the microscopic day 28 BM blast count is a
strong and independent prognostic factor in pediatric
relapsed AML. It has better discriminative value than the
time to relapse or the day 15 BM status. Treatment evalu-
ation on day 28 of therapy still allows treatment modifica-
tions, which might eventually improve the poor outcome
that patients with >20% leukemic blasts at that time-point
currently face. Additional techniques, such as multicolor
immunophenotyping, are likely to improve the discrimi-
nation between normal and leukemic blasts at early time
points, and may add benefit to risk-group adapted therapy
in pediatric relapsed AML.
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